These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 28551891)

  • 1. [BISPHOSPHONATES AND OCULAR INFLAMMATION].
    Rappoport D; Leiba H
    Harefuah; 2017 Feb; 156(2):71-73. PubMed ID: 28551891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bilateral uveitis secondary to bisphosphonate therapy.
    Tan YL; Sims J; Chee SP
    Ophthalmologica; 2009; 223(3):215-6. PubMed ID: 19221448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonates Related Ocular Side Effects: A Case Series and Review of Literature.
    Gendelman O; Tripto-Shkolnik L; Vered I; Lidar M
    Ocul Immunol Inflamm; 2022; 30(7-8):1995-1999. PubMed ID: 34014797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisphosphonates: from grandparents to grandchildren.
    Srivastava T; Alon US
    Clin Pediatr (Phila); 1999 Dec; 38(12):687-702. PubMed ID: 10618761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paget's disease: ocular complications of disodium pamidronate treatment.
    O'Donnell NP; Rao GP; Aguis-Fernandez A
    Br J Clin Pract; 1995; 49(5):272-3. PubMed ID: 7492469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonates in the treatment of disorders of mineral metabolism.
    Singer FR; Minoofar PN
    Adv Endocrinol Metab; 1995; 6():259-88. PubMed ID: 7671099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postmarketing surveillance rates of uveitis and scleritis with bisphosphonates among a national veteran cohort.
    French DD; Margo CE
    Retina; 2008 Jun; 28(6):889-93. PubMed ID: 18536608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis.
    Rizzoli R; Burlet N; Cahall D; Delmas PD; Eriksen EF; Felsenberg D; Grbic J; Jontell M; Landesberg R; Laslop A; Wollenhaupt M; Papapoulos S; Sezer O; Sprafka M; Reginster JY
    Bone; 2008 May; 42(5):841-7. PubMed ID: 18314405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aminobisphosphonate-associated orbital and ocular inflammatory disease.
    Keren S; Leibovitch I; Ben Cnaan R; Neudorfer M; Fogel O; Greenman Y; Shulman S; Zur D; Habot-Wilner Z
    Acta Ophthalmol; 2019 Aug; 97(5):e792-e799. PubMed ID: 30816018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bisphosphonate-associated osteonecrosis: a clinician's reference to patient management.
    Grewal VS; Fayans EP
    Todays FDA; 2008 Aug; 20(8):38-41, 43-6. PubMed ID: 18767452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe hypocalcemia following bisphosphonate treatment in a patient with Paget's disease of bone.
    Whitson HE; Lobaugh B; Lyles KW
    Bone; 2006 Oct; 39(4):954-8. PubMed ID: 16769264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Skeletal bone diseases impact the periodontium: a review of bisphosphonate therapy.
    Palomo L; Liu J; Bissada NF
    Expert Opin Pharmacother; 2007 Feb; 8(3):309-15. PubMed ID: 17266466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates.
    Farrugia MC; Summerlin DJ; Krowiak E; Huntley T; Freeman S; Borrowdale R; Tomich C
    Laryngoscope; 2006 Jan; 116(1):115-20. PubMed ID: 16481822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonates and osteonecrosis of the jaws: science and rationale.
    Gutta R; Louis PJ
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Aug; 104(2):186-93. PubMed ID: 17448709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Avascular mandibular osteonecrosis in association with bisphosphonate therapy: a report on four patients.
    Friedrich RE; Blake FA
    Anticancer Res; 2007; 27(4A):1841-5. PubMed ID: 17649782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
    Abelson A
    Curr Med Res Opin; 2008 Mar; 24(3):695-705. PubMed ID: 18226324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ocular side effects associated with bisphosphonates.
    Fraunfelder FW
    Drugs Today (Barc); 2003 Nov; 39(11):829-35. PubMed ID: 14702129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternative indications for bisphosphonate therapy.
    Landesberg R; Eisig S; Fennoy I; Siris E
    J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):27-34. PubMed ID: 19371812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Bisphosphonates: indications in bone diseases other than osteoporosis].
    Abdelmoula LC; Ben M'barek R; Ben Hadj Yahia C; Tekaya R; Testouri N; Chaabouni L; Zouari R
    Tunis Med; 2011 Jun; 89(6):511-6. PubMed ID: 21681711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bilateral Acute Anterior Uveitis and Conjunctivitis following Intravenous Zoledronic Acid.
    Chatterjee S; Agrawal D
    J Assoc Physicians India; 2017 Jul; 65(7):110-111. PubMed ID: 28792180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.